2004~2007年山东省部分结核分枝杆菌耐药情况检测分析  被引量:13

Study of the Status of Drug Resistant Tuberculosis in 12 Counties in Shandong

在线阅读下载全文

作  者:王海英[1] 王燕[1] 于春宝[1] 左云[1] 王俊玲[1] 刘志敏[1] 

机构地区:[1]山东省胸科医院汉光国际感染性疾病研究中心,山东济南250013

出  处:《预防医学论坛》2008年第12期1075-1076,1080,共3页Preventive Medicine Tribune

基  金:山东省科学技术发展计划(2007GG20002029);山东省科学技术发展计划(2006GG2202001)

摘  要:[目的]了解山东省结核病病原的耐药情况。[方法]对2004年5月至2007年12月山东省12个县级结核分枝杆菌防治所分离的2 637株结核分枝杆菌复合群的药敏检测情况进行分析。[结果]检测2 637株菌,对4种一线抗结核药物的总耐药率为18.85%,初始耐药率为17.83%,获得性耐药率为29.65%,耐多药率为2.43%。检测耐多药结核分枝杆菌中传代生长的41株菌株,对4种二线抗结核药物的总耐药率为72.61%,符合广泛耐多药定义的占17.07%。初治病人和复治病人耐药率和耐多药率,0~17岁组、40~59岁组、60岁以上组、18~39岁结核病病例分离的菌株间的差异均无统计学意义(P〉0.05)。[结论]山东省12个县级结核病防治所分离的结核分枝杆菌复合群耐药和耐多药率均较高。[Objective]To Study the status of drug resistant tuberculosis in 12 counties in Shandong Province.[Methods]The status of drug resistance of 2 637 Mycobacterium complex isolates collecting from 12 county tuberculosis dispensaries from May,2004 to December,2007 was analyzed.[Results]The total drug resistance rate of the 2 637 mycobacterium complex isolates for four kinds first-line anti-tuberculosis drugs was 18.85%,the initial drug resistance was 17.83%,the acquired drug resistance was 29.65%,the multi-drug resistance rate was 2.43%.41 isolates grew when 64 MDR isolates were sub-cultured and be tested for four kinds second-line anti-tuberculosis drugs,The total drug resistance rate was 72.61%,the ratio of XDR and MDR was 17.07%.there were no statistical significance on the drug resistance rate and the multi-drug resistance rate in initial cases and retreatment cases among the group of 0-17years,18-39 years,40-59 years and above 60years.[Conclusion]The results suggested that the drug resistance rate and multi-drug resistance rate of Mycobacterium complex isolates collecting from 12 county tuberculosis dispensaries still rank high.

关 键 词:结核分枝杆菌 肺结核 药物耐受性 

分 类 号:R521[医药卫生—内科学]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象